Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia (NCT03551210), a randomized phase 3 study. The primary outcome is Number of Patients With Clinical Success as Judged by the Investigator.

2. Clinical Question

The clinical question is therefore about comparative clinical response under the trial’s treatment regimens, not simply about whether either drug was followed by improvement. The success definition required improvement or resolution of pneumonia signs and symptoms without worsening or new symptoms, no need for additional antibiotic therapy, and chest roentgenograms or CT scans that were cured or improved. These elements combine clinical assessment, additional treatment use, and imaging status.

The record identifies five secondary outcomes by name: investigator-judged clinical success, infection relapse, time to switch from intravenous to oral therapy, need for other antibiotic treatment, and microbiological success. It lists 11 outcome measures and 10 analyses, but does not supply corresponding outcome estimates in the information available for interpretation. The central comparative question is consequently clear, while the magnitude and precision of the primary treatment contrast are not reported in the registry record.

3. Trial Design

This was a Phase 3, randomized, double-blind, parallel-group controlled study sponsored by R-Pharm. The official title describes it as international and multicenter, with intravenous and oral nemonoxacin compared with Tavanic® in adults with community-acquired pneumonia. The registry lists an enrollment of 342 and a completed status. The recorded study start was 2016-05-04, and primary completion was 2017-12-13.

The intervention descriptions indicate a double-dummy approach: each treatment sequence paired an active infusion with a placebo infusion, then switched participants to oral treatment. Nemonoxacin was infused at 500 mg daily over 90-110 minutes, followed by a placebo infusion over a minimum of 60 minutes. Tavanic® was infused at 500 mg daily over a minimum of 60 minutes, preceded by a placebo infusion over 90-110 minutes. The nemonoxacin arm description specifies subsequent oral nemonoxacin at 500 mg once daily. Both descriptions state that participants switched from intravenous to oral therapy; the full oral Tavanic® dosing details are not reported in the registry record.

Randomization and double masking are important design features for interpreting an assigned-treatment comparison. Randomization is intended to reduce systematic differences between treatment groups at baseline, while masking can reduce the influence of treatment knowledge on care and outcome assessment. These are general design principles; the registry record does not report the sequence-generation method, allocation concealment details, or how masking was maintained in practice.

The primary endpoint was assessed in a modified Intent-To-Treat population rather than being described only for all randomized participants. The registry defines that population using receipt of at least one study dose, satisfaction of minimum disease criteria, and at least one efficacy assessment. Reasons for any differences between enrollment, treatment exposure, and outcome denominators are not reported in the registry record. The registry also does not report the planned duration of treatment or the precise operational rules for switching route beyond the listed time-to-switch secondary outcome.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Modified Intent-To-Treat population (mITT) - all randomized patients received at least one dose of investigational drugs, in compliance with at lest minimal disease criteria (inclusion criteria 3 and 4) and had at least one assessment of clinical efficacy in this study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Modified Intent-To-Treat population (mITT) - all randomized patients received at least one dose of investigational drugs, in compliance with at lest minimal disease criteria (inclusion criteria 3 and 4) and had at least one assessment of clinical efficacy in this study

6. Primary Endpoint

The registry lists the primary outcome as Number of Patients With Clinical Success as Judged by the Investigator, measured over Visit 4 (within 7-9 days after last dose).

The primary endpoint is the number of participants judged by the investigator to have clinical success at Visit 4, within 7-9 days after the last dose. The registry defines success using several conditions: pneumonia signs and symptoms must be resolved or improved, without worsening or new pneumonia symptoms; additional antibiotic therapy must not be required; and chest roentgenograms or CT scans must be cured or improved.

This kind of composite clinical assessment is used to capture more than a single symptom or laboratory measure. It combines the clinical course, the need for further antibiotic treatment, and imaging findings. In general, defining success in advance can make the intended outcome more consistent across participants and centers, although the meaning of a composite depends on its components and decision rules. Here the registry gives the component criteria, but does not report how each component contributed to the final classification or whether adjudication was used.

The time point matters because clinical status may change during treatment and follow-up. The specified assessment occurred after the last dose, within the registry’s stated Visit 4 window. No result counts by treatment group, effect estimate, confidence interval, or p value for this endpoint are reported in the registry record. The listed outcome is therefore interpretable as a definition of what was assessed, but not as evidence about the size or precision of a treatment difference.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods determine how trial observations are turned into estimates and how uncertainty is described. The design information in the registry record establishes randomization, masking, a parallel-group structure, and an intended clinical-success assessment. It does not provide a complete statistical analysis plan. The concepts below are general explanations of how such analyses are commonly interpreted, not claims about procedures used in this trial unless explicitly stated in the registry record.

What does randomization contribute?

In general, randomization assigns participants to treatment groups by chance. Its purpose is to make treatment assignment independent of measured and unmeasured participant characteristics in expectation, so that a between-group outcome contrast can be interpreted as a treatment comparison, subject to adherence, missing data, and analysis assumptions. Randomization does not guarantee that every characteristic is balanced in a particular trial. The registry confirms randomized allocation but does not describe the randomization sequence, blocking, stratification, or allocation concealment.

Double masking is also stated. As a general principle, masking can help limit differences in care or assessment that arise from knowing the assigned treatment. A double-dummy regimen can support masking when the treatment schedules differ, by pairing active treatment with placebo procedures. The intervention descriptions include placebo infusions alongside active infusions. The registry does not give details of who remained masked, whether masking was assessed, or how any possible unmasking was handled.

What does the primary outcome measure?

The endpoint is a participant-level clinical-success classification at a specified follow-up visit. For a binary outcome, each participant is classified into an outcome category such as success or no success, and group results are commonly expressed as counts, proportions, and a contrast between groups. These are general statistical descriptions. The registry’s outcome name is a count, but the recorded primary outcome information has several categories or time points and is not reduced to a single comparison. The group counts and any treatment contrast are not reported in the registry record.

The composite success criteria make the definition clinically multidimensional. General interpretation of a composite endpoint should consider whether its components have similar importance and whether one component can dominate the overall result. The record describes the criteria but does not report component-specific results or the rule used to combine them beyond the stated success definition. It also does not report whether endpoint assessors were independent or whether an adjudication process was used.

How should uncertainty be understood?

A point estimate describes the observed treatment contrast under a particular analysis. A confidence interval indicates the uncertainty around that estimate under the model and assumptions used. A p value, when reported, addresses compatibility of the observed data with a specified null hypothesis; it does not measure the size or clinical importance of an effect. These are general statistical concepts. The registry information does not give a primary point estimate, confidence interval, or p value, so neither effect size nor precision can be judged for the primary outcome.

For a binary outcome, the selected effect measure matters. A difference in event proportions and a ratio of proportions answer different questions and can yield different numerical impressions. The registry record does not identify a single reported primary comparison or effect measure in the outcome information at issue. No new estimate can be reconstructed from a missing result count.

Why do populations and denominators matter?

Analysis populations define which randomized participants contribute to an estimate. The registry defines a modified Intent-To-Treat population that requires at least one dose, minimum disease criteria, and at least one clinical efficacy assessment. In general, restricting analysis based on post-randomization events can affect comparability if exclusions differ by treatment or relate to outcome. Whether that concern applies depends on actual participant flow and the prespecified analysis rules. The record does not report participant flow, exclusions by arm, or a comparison between the modified population and other analysis populations.

Denominators should therefore be read outcome by outcome. The safety counts use 171 participants at risk for each listed nemonoxacin safety category and 169 for each listed Tavanic® category. Those figures are not the same information as the primary efficacy population definition. The registry does not explain the relationship between the enrollment count, efficacy population, and safety denominators.

What is over-dispersion, and does it apply?

Over-dispersion is a general issue in count or rate models when observed variability is greater than a model assumes. It can make standard errors too small if the extra variability is ignored. The primary outcome is described as a participant count, not a rate model, and the registry does not report an over-dispersion model or any fitted model details. It would therefore be inappropriate to assert that over-dispersion was assessed or relevant to the primary analysis.

The registry gives a general basis for sample-size illustrations: an observed-effect planning illustration, two-sided significance level 0.05, equal allocation, and a normal approximation; time-to-event calculations use total events, while other calculations are expressed as participants per arm. These are planning assumptions, not evidence that the trial used those methods for its design. The sample-size rationale and the trial’s own design calculations are not reported in the registry record. An illustration based on an observed effect is not observed power and should not be treated as a result from the randomized comparison.

10. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when several outcomes, time points, treatment contrasts, or analyses are examined. In general, making many statistical tests without an appropriate plan can increase the chance of at least one apparently notable result arising by chance. A prespecified hierarchy, adjustment procedure, or clearly defined primary comparison can help readers understand how results should be interpreted. The registry lists 11 outcome measures and 10 analyses, and identifies several secondary outcomes, but multiplicity handling is not reported in the registry record. The record does not say whether any adjustment, hierarchy, or gatekeeping strategy was planned.

The primary outcome information itself is not presented as a single comparison: it has several categories or time points and is not reduced to one treatment contrast. This prevents a direct reading of a primary estimate and leaves the precise inferential target unclear from the registry outcome information. The record does not report whether the endpoint categories were intended as separate analyses, how they would be ordered, or which result would be considered primary for inference.

Missing-data methods are also not reported in the registry record. For a participant-level clinical endpoint, missing assessments can affect the numerator, denominator, or both, depending on the prespecified handling rule. In general, complete-case analysis, imputation, and assigning an unfavorable outcome to missing participants embody different assumptions. The registry does not identify the method used, the amount of missing primary-outcome data, or any sensitivity analysis. These omissions matter because the modified Intent-To-Treat definition requires at least one clinical efficacy assessment, which excludes participants without such an assessment from that specified population.

The registry defines the modified Intent-To-Treat population, but does not report other analysis populations, deviations from assigned treatment, or the primary analysis population’s exact arm-specific size. It also does not report interim analyses, stopping rules, or a full statistical analysis plan. These items cannot be inferred from the Phase 3 designation, the randomization, or the existence of secondary outcomes.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (0.6%), respiratory failure (0.6%).

The registry reports serious adverse events and other adverse events separately, with the number at risk and the number affected in each treatment group. For serious adverse events, 0 of 171 participants were affected in the nemonoxacin group and 2 of 169 were affected in the Tavanic® group. The registry reports 0 deaths in both groups. For other adverse events, 86 of 171 participants in the nemonoxacin group and 67 of 169 in the Tavanic® group were affected.

These figures describe observed counts in the listed safety groups. They are not, by themselves, an adjusted comparison or a test of whether the treatment groups differ. No confidence intervals or statistical tests for these safety counts are reported in the registry record. The denominators should be retained when reading the counts, and no rate or difference should be inferred beyond the figures explicitly reported.

The registry also lists Pneumonia and Respiratory failure among the top serious adverse-event terms, each at 0.6%. The record does not link those percentages to a specific treatment group in the information available. The terms should not be used to assign a cause or infer which group experienced them.

Adverse-event counts do not establish that an event was caused by a study treatment. Details about seriousness criteria, event onset, duration, severity grades, relatedness assessments, and withdrawals due to adverse events are not reported in the registry record. These counts therefore provide a limited descriptive safety account rather than a complete comparative safety analysis.

12. What the Result Does, and Does Not, Mean

The record supports a clear description of the trial’s purpose and design: adults with community-acquired pneumonia were randomized in a double-blind, parallel-group study of nemonoxacin versus Tavanic®. It also defines clinical success using symptoms, additional antibiotic use, and imaging, and gives selected safety counts. These details help readers understand what the investigators intended to compare and how some events were recorded.

The record does not report the primary clinical-success counts or a single comparative estimate. Consequently, it cannot establish the direction or magnitude of a difference between treatment groups, or how precise such a difference might be. The objective to evaluate comparative efficacy is not itself an efficacy finding. The endpoint definition does not show how many participants succeeded, and the secondary outcome names do not reveal their results.

The safety information is also limited. Serious adverse events and other adverse events are reported as counts with denominators, and deaths are reported as zero in both groups. These figures can be read as descriptive observations, but there is no reported uncertainty estimate or inferential comparison for them. The listed serious-event terms are not assigned to a particular group in the available registry information. The counts therefore should not be interpreted as proof of a treatment effect or proof of no treatment effect.

In general, a randomized design can support a causal comparison when its conduct, outcome ascertainment, analysis, and missing-data handling are appropriate. That general principle does not replace the need for reported results and methods. The registry record does not report enough information to assess the primary estimate, the handling of missing outcomes, multiplicity, or the analysis plan.

Accordingly, the most defensible reading is bounded: the trial was designed to compare two treatment regimens, and the record documents selected aspects of its design, endpoint, and safety reporting. It does not provide the primary comparative outcome needed to quantify the central question. No conclusion about whether one treatment produced greater clinical success can be drawn from the record information described.

13. Why This Trial Matters Statistically

This trial is statistically notable because it combines a randomized, double-blind parallel design with a clinical-success outcome that integrates several forms of evidence. The endpoint includes the course of symptoms, whether additional antibiotics were needed, and imaging status. Such an outcome can reflect the broader clinical response, but it also makes transparent definition and reporting especially important: readers need to know how success was classified and what the group results were.

The registry makes the endpoint criteria and assessment timing explicit, including the Visit 4 window within 7-9 days after the last dose. It also defines a modified Intent-To-Treat population. These details are relevant to interpretation because results can depend on the assessment time and the population included. The record does not, however, give the arm-specific primary outcome counts or a single treatment-effect estimate. The statistical question is identifiable, but its answer cannot be quantified from the reported primary outcome information.

The contrast between design information and outcome reporting is an important lesson for reading trial registries. Randomization and masking describe ways a study aims to limit bias; they do not demonstrate the size or precision of an outcome effect. Similarly, a sample-size planning illustration based on an observed effect is not observed power, and it is not evidence about the result. The registry’s stated assumptions identify how such illustrations are framed, but the trial’s own sample-size justification is not reported.

The safety data further illustrate why denominators and outcome definitions matter. The registry gives serious-event and other-event counts for each group, but counts alone do not provide uncertainty or explain attribution, severity, or timing. The listed serious-event percentages are not connected to a treatment group in the reported information. Careful statistical interpretation distinguishes these descriptive observations from a comparative conclusion.

For clinical researchers and biostatisticians, the key issue is alignment: the stated objective, endpoint definition, analysis population, statistical plan, and reported estimates should be traceable to one another. In this record, important design elements are described, while the primary estimate, uncertainty, missing-data approach, and multiplicity strategy are not reported. That gap limits what can be learned about the comparative clinical outcome.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is that the registry record does not report a single primary clinical-success comparison. The outcome is identified as having several categories or time points and is not reduced to one comparison. There are no primary group counts, effect estimate, confidence interval, or p value in the outcome information described, so the comparative efficacy result cannot be evaluated for magnitude or precision.

Further limitations concern statistical transparency. The registry does not report the trial’s sample-size justification, complete statistical analysis plan, multiplicity strategy, interim analyses, or stopping rules. Missing-data handling and the amount of missing primary-outcome data are also not reported. The record defines a modified Intent-To-Treat population, but does not provide its arm-specific size or participant flow. These gaps prevent assessment of how exclusions, missing assessments, or analysis choices may have affected the result.

The endpoint combines clinical symptoms, additional antibiotic use, and imaging. Although the criteria are described, component-specific results and details of endpoint adjudication are not reported in the registry record. Readers therefore cannot determine which elements most often influenced the success classification or how consistently assessments were applied across centers.

Safety reporting is limited to selected counts and terms. The record does not report event severity, timing, duration, causal attribution, withdrawals due to adverse events, or uncertainty estimates for group comparisons. The two serious-event terms and their percentages are not assigned to a specific group in the reported information. The differing safety denominators also cannot be reconciled with enrollment or efficacy populations from the details reported.

The treatment descriptions establish intravenous treatment and subsequent oral therapy, but the full oral Tavanic® regimen is not reported in the registry record. More generally, details of randomization implementation, masking maintenance, protocol deviations, and the study’s own design calculations are absent. These limitations do not negate the design information that is reported, but they restrict independent assessment of conduct and interpretation.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia — NCT03551210.
• Registry record last updated 2023-02-16; status last verified 2023-01.
• Results first posted 2023-02-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03551210 is a completed Phase 3 randomized, double-blind, parallel-group trial sponsored by R-Pharm. It enrolled 342 adults in a study comparing intravenous and oral nemonoxacin with Tavanic® for community-acquired pneumonia. The recorded start date was 2016-05-04, and primary completion was 2017-12-13.

The primary outcome was investigator-judged clinical success at Visit 4, within 7-9 days after the last dose, defined by improvement or resolution of pneumonia signs and symptoms, no additional antibiotic requirement, and cured or improved imaging. The registry does not report a single primary comparison or its result. Serious adverse events affected 0 of 171 participants in the nemonoxacin group and 2 of 169 in the Tavanic® group; deaths were 0 in both groups. Other adverse events affected 86 of 171 and 67 of 169, respectively. The registry does not report the primary estimate, its precision, or key statistical-plan details.